Loading...
 
Επιστροφή στη λίστα
Article Links
Πρόβλεψη της κλινικής απάντησης σε Βιολογική Θεραπεία (abatacept) ασθενών με Ρευματοειδή Αρθρίτιδα βάσει ανοσοφαινοτυπικής ανάλυσης περιφερικού αίματος
Πρόδρομος Σιδηρόπουλος1,3, Παναγιώτης Βεργίνης2, Γαρυφαλιά Παπαδάκη3, Γιώργος Μπερτσιάς3, Αργυρώ Ρέπα1, Νέστορας Αυγουστίδης1
Πληροφορίες Συγγραφέων

1: Ρευματολογική Κλινική, Ιατρική σχολή,  Πανεπιστήμιο Κρήτης
2: Ίδρυμα Ιατροβιολογικών Ερευνών, Ακαδημίας Αθηνών
3: Εργαστήριο Ρευματολογίας, Αυτοανοσίας και Φλεγμονής, Ιατρική σχολή,  Πανεπιστήμιο Κρήτης

Λέξεις Κλειδιά: ρευματοειδής αρθρίτιδα, κυτταροκίνες, βιοδείκτες, πρόβλεψη απάντησης
Παραπομπές
  1. Cross M, Smith E, Hoy D, Carmona L, Wolfe, F, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73:1316-22.
  2. Lundqvist J, Kastang F, Kobelt G, and Jonsson B. The burden of rheumatoid arthritis and access to treatment: determinants of access. Eur J Health Econ 2008;2:S87-93.
  3. Smolen J S, Landewe R, Breedveld F, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73;492-509.
  4. Flouri I, Markatseli T E, Voulgari P V, Boki K A, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2014;43:447-57.
  5. van den Broek M, Visser K, Allaart C F, Huizinga T W. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol 2013;13:463-9.
  6. Carreno B M, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53.
  7. Tivol E A, Borriello F, Schweitzer A N, Lynch W P, Bluestone J A, Sharpe A H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 1995;3:541-7.
  8. Linsley P S, Brady W, Urnes M, Grosmaire L S, Damle N K, Ledbetter J A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9.
  9. Bathon J, Robles M, Ximenes A C, Nayiager S, Wollenhaupt J, Durez P, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011;70;1949-56.
  10. Genovese M C, Becker J C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
  11. Kremer J M, Genant H K, Moreland L W, Russell A S, Emery P, Abud-Mendoza C, et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-63.
  12. Schiff M, Weinblatt M E, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73;86-94.
  13. Weinblatt M E, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65:28-38.
  14. Hetland M L, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen I T. et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
  15. Maneiro R J, Salgado E, Carmona L, Gomez-Reino J J. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum 2013;43:9-17.
  16. Scarsi M, Ziglioli T, Airo P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 2011;38;2105-11.
  17. Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, et al. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study. Rheumatology (Oxford) 2015;54:854-9.
  18. Arnett F C, Edworthy S M, Bloch D A, McShane D J, Fries J F, Cooper N S, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum 1998;31;315-24.
  19. Kavousanaki M, Makrigiannakis A, Boumpas D, Verginis P. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum 2012;62:53-63.
  20. van Gestel A M, Haagsma CJ, van Riel P L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41;1845-50.
  21. Prevoo M L, van't Hof M A, Kuper H H, van Leeuwen M A, van de Putte L B, van Riel P L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
  22. Smolen J S, Breedveld F C, Schiff M H, Kalden J R, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice, Rheumatology (Oxford) 2003;42;244-57.